Loading...

Advancing Care in XLH: Applying Newly Published Int'l Treatment Guidelines

Saturday, October 10, 2026

CME Satellite Symposium at the ASBMR, John B. Hynes Veterans Memorial Convention Center

900 Bolston Street

Boston, MA

Meeting Room TBA

You must be registered for the ASBMR annual meeting to attend this live in person presentation. 

X-linked hypophosphatemia (XLH) is the most common heritable form of rickets, affecting approximately 1 in 20,000 individuals. Characterized by stunted growth with disproportionate short stature, lower limb bowing, reduced motor function, osteoarticular pain, hypotonia, and dental and periodontal complications, XLH is a progressive, lifelong bone disorder. Despite increasing recognition of the disease, diagnosis is often delayed, and many patients do not receive timely or appropriate treatment, resulting in preventable long-term morbidity.

With the release of new global clinical practice guidelines for X-linked hypophosphatemia (XLH), opportunities have emerged to improve early recognition and optimize lifelong management. Using pediatric and adult case studies, this CME-accredited activity reviews consensus recommendations, strategies for early diagnosis, risk assessment, long-term monitoring, and approaches to individualized treatment, including who to treat and when. Current and emerging therapies will also be discussed.

Join us as we discuss actual patient cases using the new guidelines demonstrating improvement in patient diagnosis and outcomes

Schedule

* Times are EST
12:45 PM Registration and Boxed Lunches
12:55 PM Welcome, Disclosure, Supporter Acknowledgement
01:00 PM Overview of Newly Published International XLH Treatment Guidelines

Key recommendations, evidence base, and implications for endocrinology practice
Case-Based Discussion: Pediatric and Adult XLH
Clinical presentation, diagnostic challenges, and multisystem complications
Monitoring Disease Progression and Management
Biochemical monitoring, imaging considerations, treatment optimization, and guideline-directed follow-up

01:50 PM Audience Q&A
02:00 PM Adjourn
02:00 PM Online evaluation

Presenters

Jill H. Simmons, MD

Interim Director, Division of Pediatric Endocrinology
Professor of Pediatrics, Pediatric Endocrinology
Director, Program for Pediatric Metabolic Bone Disorders
Vice Chair for Faculty Development, Department of Pediatrics
Member, VUMC Academy for Excellence in Education
Vanderbilt University Medical Center
Nashville, TN

Thomas J. Weber, MD

Medical Director, Duke Clinical Bone Laboratory
Professor of Medicine
Division of Endocrinology, Metabolism, and Nutrition
Duke University Medical Center
Durham, NC

Accreditation

EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Canadian CME: Through an agreement between the ACCME and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 1 of the Royal College’s MOC Program.

The UEMS-EACCME®: The American Medical Association has an agreement of mutual recognition of CME credit with the UEMS (European Union of Medical Specialists). Under the terms of this agreement the European Accreditation Council for Continuing Medical Education (EACCME), the accrediting arm of the UEMS, will convert CME credit for live activities certified by the AMA.

Physician Assistants: AAPA and the NCCPA accept AMA Category 1 Credit™ from organizations accredited by the ACCME. 

Nurse Practitioners: AANP and the ANCC accept AMA Category 1 Credit™ from organizations accredited by the ACCME.  

Educational Objectives

At the conclusion of this conference, you should be able to:
  • Recognize the age-specific clinical, biochemical, and radiographic features of XLH in pediatric and adult patients to reduce diagnostic delay and misdiagnosis
  • Implement guideline-recommended diagnostic and monitoring strategies, including interpretation of phosphate metabolism, FGF23-related abnormalities, and long-term surveillance for disease complications
  • Assess the comparative benefits, limitations, and clinical indications of conventional therapy vs. Burosumab to guide evidence-based treatment selection and guidelines recommendations
  • Integrate international XLH clinical practice guidelines into individualized management plans that address skeletal health, pain, functional outcomes, and quality of life across the lifespan

Supporter

KYOWA KIRIN